Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE)

NCT01331525 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT01331525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01331525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of the Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (ICE)
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
June 30, 2015
Enrollment
42 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer